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The ability of IgM antibodies to specifically enhance the thymus-dependent hu-
moral immune response to particulate antigens is well documented (1-5). The re-
quirements for the potentiation by IgM are that a suboptimal dose of the antigen
is used (1) and that an in vivo system is used (5). The IgM-mediated enhancement
requires presence of T cells (6).
In the present study the importance of activation of complement factors for the
ability of IgM to induce enhancement was investigated. We found that mutant IgM
antibodies unable to activate complement lack the enhancing properties of the wild-
type IgM. Moreover, IgM cannot enhance the immune response in mice depleted
ofcomplement by treatment with cobra venom factor. The significance of these findings
with regard to the mechanism behind IgM-mediated enhancement and cobra venom
factor (CVF)-induced immunosuppression is discussed.
Materials and Methods
Mice.
￿
Male CBA/Ca and AKR mice, 10-16 wk old, from A-lab, Stockholm, Sweden and
our own breeding facilities were used.
Antigens.
￿
SRBC and HRBC were purchased from the National Veterinary Institute,
Hátunaholm, Sweden. Erythrocytes were stored in sterile Alsevers solution at 4°C. TNP was
coupled to SRBC according to Rittenberg and Pratt (7). The amount of TNP coupled is
given as microgram/milliliter packed erythrocytes.
Antibodies.
￿
Polyclonal IgM was derived from sera of CBA/Ca or AKR mice 6 d after an
intraperitoneal injection of 1070 SRBC in PBS and prepared as described (3). The hybrid-
omas producing the wild-type and mutant 13 IgM-antiTNP antibodies are described else-
where (8). mAbs used in this study were isolated from cell culture supernatants by ammo-
nium sulphate precipitation followed by gel filtration on a Sephacryl S-300 column .
HemagglutinationIHemolysis.
￿
The hemagglutination and hemolytic titers are defined as the
highest antibody dilution able to agglutinate or lyse a 0.257o suspension of SRBC or SRBC-
TNP,oo in the presence of guinea pig complement (lysis only) aftera 1-h incubation at 37°C.
CVFTreatment.
￿
Mice were injected intraperitoneally with four doses of0 .1 ml of 100 U/ml
CVF from Naja haje (Cordis Laboratories Inc., Miami, Florida) during 24 h. Control groups
received PBS in the same regimen: All mice were bled individually from the tail 7 d before
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FIGURE 1 .
￿
Effect ofcomplement depletion on IgM-induced
enhancement ofthe antibody response in mice. Two groups
of CBA/Ca mice were injected intraperitoneally with CVF .
Two control groups received PBS in the same regimen. 2
h after the lastCVF injection all mice were bled from their
tails in order to titerC3 . Another2h later, oneCVFgroup
and one control group received intravenous injections of
0.1 ml murine, polyclonal IgM-antiSRBC (hemolytic titer
2,048) . 1 h later all groups were immunized intravenously
with 4 x 10 5 SRBC (10 mice in two different experiments)
together with 2 x 10 5 HRBC (horse erythrocytes) . ("")
p < 0.001 vs. the respective control group . Mice injected
only with IgM-antiSRBC generated 65 PFC/spleen (not
shown). No significant enhancement of PFC anti-HRBC
was found (not shown) .
Sera from the individual mice (bled 7 d before and 2 h
after CVF treatment) were assayed for C3 by radial im-
munodiffusion against goat anti-mouse C3 antibodies .
Mean titer was 6.3 ± 1.3 (SEM) after and 45 .6 ± 6.5 be-
fore CVF treatment .
the first injection and 2 h after the last . C3 levels in sera were assayed by radial immunodiffusion
using a goat anti-mouse C3 antiserum (CooperBiomedical, Inc., Malvern, PA).
Immunizations .
￿
Groups of at least four mice were immunized as described in the figure
legends.
Enzyme-linked Immunosorbent Assay.
￿
SRBC-specific IgG antibodies in sera were assayed in
an ELISA, as described elsewhere (9) .
PFC Assay.
￿
A modified version of theJerne hemolytic plaque assay was performed (3) .
The p values were estimated by Student's t test .
Results and Discussion
In vivo administration of CVF causes transient depletion of plasma C3 to <5%
of normal due to activation ofC3 via the alternative pathway (10) . Mice were treated
with CVF and then challenged with polyclonal IgM-antiSRBC and SRBC . This
procedure abrogated the five- to sixfoldenhancing effecton thedirect PFC response
of IgM seen in normal mice immunized with 4 x 105 SRBC (Fig. 1) . Moreover,
no elevation of the IgG-anti-SRBC levels in sera ofCVF and IgM-treated mice
was detected (Table 1) . CVF from Naja haje does not deplete complement factors
that act subsequent to C3 in the complement pathway (11) . These data therefore
TABLE I
IgG-Anti-SRBC Response in Mice Treated with CVF before Specific
IgM-induced Enhancement
p vs .
control
0.001
NS
Sera from the same mice as described in Fig . 1 were prepared on the day of
PFC test and stored at -20°C . They were tested for IgG-anti-SRBC in 1 :10
dilutions in an ELISA . Values are expressed as absorbance at 405 nm .
Treatment Dose of SRBC A405 (SD)
Number
of mice
- 4 x 105 0.177 (0.071) 10
IgM 4 x 105 0.429 (0.157) 10
CVF 4 x 105 0.137 (0.035) 10
CVF + IgM 4 x 105 0.165 (0.064) 103000
0.0025 0.025 0.25
Dilution of antibodies
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indicate that the early complement factors are crucial in the enhancing process . To
confirm this, AKR mice, which are genetically deficient of C5 (12), were injected
with SRBC-specific IgM and SRBC and the enhancement of the anti-SRBC re-
sponse in these mice was compared with that in similarly treated CBA/Ca mice having
normal C5 levels . It is clearly demonstrated that IgM is a potent enhancer also of
the humoral immune response in AKR mice (Fig . 2) .
Next, we compared the effects on the antiSRBC response of a monoclonalTNR
specific IgM and a mutant of this antibody, IgM13, which has <1% the normal ca-
pacity to activate complement due to a single amino acid substitution (8) . Mice were
immunized with SRBCTNP with or without IgM-antiTNP of either the wild or
mutant type, with the same hemagglutinating titers . Since IgM is known to enhance
the response against all different epitopes on an antigen equally well (3), the PFC
response against SRBC was measured . The wild-type antibody enhanced the re-
sponse in a dose-dependent fashion, whereas the mutant antibody failed to induce
any significant enhancement (Fig . 3) .
In amodel forIgM-mediated enhancement ofthe humoralimmune response there
200 1
FIGURE 2 .
￿
Efficient IgM-mediated enhancement in C5- AKR mice.
CBA/Ca orAKR mice were injected intravenously with IgM-anti-
SRBC (hemolytic titer 4,096) either from CBA/Ca (stippled bars) or
AKR (striped bars) sera followed after 1 h by 4 x 105 SRBC . Control
groups (open bars) received antigen alone . The PFC numbers in IgM-
injected groups were always significantly higher than controls (p <
0.001) .
FIGURE 3 .
￿
Effect ofcomplement activating and nonactivating
IgM-antiTNP antibodies on the antibody response in mice .
Groups of CBA/Ca mice (as in Fig . 1) were injected intrave-
nously with 0 .1 ml of either PBS (dotted line), wild-type IgM
(O) or mutant 13 IgM ("). 1 h later all groups were immunized
intravenously with 4 x 104 SRBCTNPS in 0 .1 ml PBS. The
undiluted IgM preparations both had hemagglutinating titers
of 1 :6,400 against SRBCTNPioii . The wild-type antibodies
had a hemolytic titer of 1:20,480 against SRBCTNP,0o . No
hemolytic activity could be detected in the mutant prepara-
tion . Direct PFC-antiSRBC were assayed 6 d after immuni-
zation . The results (pooled from three experiments) are ex-
pressed as the geometrical mean of each group and the bars
denote antilog ofSEM . Numbers in parentheses indicate the
number of animals . ("") p < 0.001 andp < 0.01 in com-
parison to the control group.200 2
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are two main concepts to consider. The first is the central role of complement in
induction of immunological memory and normal humoral responses (reviewed in
references 13, 14). These effects have been ascribed to C3 (14). Also, patients with
C4 deficiency respond poorly to T-dependent antigens and do not develop immuno-
logical memory (15) . Our results on the effect of CVF treatment on the IgM en-
hancement are most likely due to decreased C3 levels since we used CVF from Egyptian
cobra (Naja haje) and IgM is an efficient enhancer ofthe antiSRBC response in AKR
mice. The second concept is the important role of the spleen in immune responses
affected by C3 and/or IgM potentiation. Complement is essential for efficient local-
ization of antigen to the spleen (16, 17). The IgM-mediated enhancement is paral-
leled by an increased levelof SRBC in the spleen (2). Splenectomized mice (Heyman,
B., unpublished data) as well as patients with hereditary aplasia of the spleen (18)
are poor responders to intravenously administered SRBC, the route normally used
in IgM enhancement studies.
We propose the following model for IgM enhancement of responses against par-
ticulate antigens. In the spleen, complexes of antigen- IgM-activated C3 fragments
are trapped more efficiently than antigen alone on the follicular dentritic cells (FDC),
which carry Cab receptors (19). The trapped immune complexes then capture B
cells carrying antigen-specific as well as C3 receptors. Crosslinked C3 is known to
stimulate activated B cells to proliferation and Ig secretion (20). Additional help
to these B cells may be provided by antigen-specific T helper cells that are activated
more efficiently due to increased concentrations of antigen, and possibly by IL-1
secretion by the FDC.
Thus, the mechanism behind IgM-mediated enhancement would be a more efficient
presentation of antigen and more efficient activation ofantigen sensitive B cells. This
explains why the same fine specificity (3) and isotype distribution (21) are found
in IgM-enhanced and control responses. Moreover, IgM is known to potentiate (1)
and CVF to suppress (22) the immune response only to suboptimal antigen doses.
Interestingly, IgG has been shown to enhance the primary response (23) as well
as the induction of memory (17) to soluble antigens. This has been ascribed to the
ability of the IgG antibodies to activate complement, and a hypothesis similar to
ours was proposed to explain the results (17).
Summary
The ability of IgM antibodies to specifically enhance the thymus-dependent hu-
moral immune response to particulate antigens is well documented. We have used
two approaches to test whether complement factors play a role in this process. First,
mice were depleted of C3 by treatment with cobra venom factor (CVF) and then
immunized with SRBC with or without IgM-antiSRBC . CVF treatment severely
impaired the capacity ofIgM to induce an enhanced antiSRBC response. Moreover,
it was shown that IgM can potentiate the response in C5-deficient AKR mice, thus
demonstrating that the complement factors acting before C5 are the crucial ones.
A second test compared the enhancing propertiesoftwo monoclonal IgM-antiTNP
antibodies where, because of a point mutation in the g chain constant region, one
of the antibodies is impaired in its capacity to activate complement. We show that
the mutant antibody lacks the enhancing properties of the wild-type IgM.
Activationof C3 by IgM antibodies as well as localization of antigen in the spleenHEYMAN ET AL. BRIEF DEFINITIVE REPORT
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seem to be necessary steps in the IgM-mediated enhancement of antibody responses.
Ourdata offer an explanation to the immunosuppression described in CVF-treated
animals as well as the low humoral immune responses in certain hereditary comple-
ment deficiencies. It is suggested that IgM indeed has an important physiological
function in enhancing antibody responses to foreign substances.
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